Powerful Medical Receives FDA Breakthrough Device Designation for PMcardio STEMI AI ECG Model
Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announces that its PMcardio STEMI AI ECG model has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This designation recognizes PMcardio as a breakthrough technology for the detection of ST-elevation myocardial infarction (STEMI) and STEMI equivalents—a life-threatening cardiac condition requiring immediate intervention.
Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announces that its PMcardio STEMI AI ECG model has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This designation recognizes PMcardio as a breakthrough technology for the detection of ST-elevation myocardial infarction (STEMI) and STEMI equivalents—a life-threatening cardiac condition requiring immediate intervention.
Every 40 seconds, someone in the United States suffers from a heart attack1, where rapid diagnosis is crucial to saving heart muscle and preventing long-term damage, often leading to higher mortality rates. The electrocardiogram (ECG) remains the primary tool for rapid diagnostics, yet the standard of care often fails to detect heart attacks accurately and timely, resulting in critical delays in treatment. PMcardio is the only solution capable of detecting both STEMI and STEMI equivalents on the ECG—aligning with the emerging emphasis on a paradigm shift towards Occlusion Myocardial Infarction (OMI) and bridging a vital gap in early, precise heart attack diagnosis.
“For the last 20 years, life-saving treatment exists for heart attack patients, yet far too many still don’t receive the urgent care they need due to delays in diagnosis and inefficient triage,” said Robert Herman, MD, PhD, Chief Medical Officer of Powerful Medical. This is especially critical in settings where immediate specialist evaluation isn’t available—only 17% of patients presenting to rural centers make it to the catheterization lab in time for intervention.
Dr. Herman added, “By equipping physicians and allied providers with an AI-powered tool for accurate and immediate STEMI detection, available around the clock, we can bridge this gap, ensure timely treatment, and improve patient outcomes, often preventing avoidable deaths”.
The FDA’s Breakthrough Device Designation provides PMcardio with an expedited review process and close collaboration with the agency on its path toward market authorization. This designation is reserved for technologies that offer significant advantages over existing solutions and address unmet medical needs.
This recognition underscores the FDA’s acknowledgment of Powerful Medical’s STEMI AI ECG Model, dubbed “Queen of Hearts”, to set a new standard in frontline heart attack detection and triage, ultimately enhancing care quality, accelerating treatment decisions, and saving lives through earlier and more accurate diagnosis.
“FDA Breakthrough Device Designation is a pivotal milestone in our effort to revolutionize heart attack detection and ensure every patient receives immediate, life-saving care,” said Felix Bauer, COO of Powerful Medical. “We are committed to bringing this life-saving technology to the U.S., the largest healthcare market in the world. This recognition by the FDA validates the impact of our innovation and brings us closer to transforming emergency cardiac care on a global scale,” added Martin Herman, CEO.
With this designation, Powerful Medical not only works closely with the FDA on market approval but also gains improved access to CMS reimbursement mechanisms to bring the PMcardio STEMI AI ECG Model to healthcare providers nationwide, serving U.S. public health.
Learn more about the PMcardio STEMI AI ECG model and how it’s transforming heart attack detection.
References
- 1. Tsao, C.W., Aday, A.W., Almarzooq, Z.I., et al. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. Circulation. 2023;147:e93–e621.
- 2. Jollis, J.G., Granger, C.B., Zègre-Hemsey, J.K., et al. Treatment time and in-hospital mortality among patients with ST-segment elevation myocardial infarction. JAMA. 2018–2021.
Share this article
About PMcardio
PMcardio is a CE-marked Class IIb AI medical device that interprets any 12-lead ECG — from a photo or a digital file — in seconds. It detects 50+ ECG findings, including occlusion myocardial infarction (OMI) — the acute coronary occlusions that conventional STEMI criteria miss in over half of cases. Its Queen of Hearts™ OMI model holds FDA Breakthrough Device Designation, and PMcardio is already used by 100,000+ clinicians who have analyzed more than 2.5 million ECGs.
About Powerful Medical
Powerful Medical is a medical-technology company using artificial intelligence to transform how cardiovascular disease — the world’s leading cause of death — is diagnosed. Founded in 2017, it built PMcardio, the world’s first AI medical device to detect acute coronary occlusion (OMI) from an ECG. Its research is published in the European Heart Journal – Digital Health and validated across 25+ clinical studies, and its Queen of Hearts™ model earned FDA Breakthrough Device Designation. To date, PMcardio has supported the detection of 120,000+ heart attacks across 150+ hospital deployments worldwide.
